Similar articles for PMID: 31603362

Year	Number of Results
2004	1
2007	4
2008	2
2009	2
2011	4
2012	3
2013	4
2014	9
2015	10
2016	18
2017	14
2018	14
2019	25
2020	33
2021	27
2022	32
2023	8
2024	1

1

Siponimod in the treatment of multiple sclerosis.

Goodman AD, Anadani N, Gerwitz L. Goodman AD, et al. Expert Opin Investig Drugs. 2019 Dec;28(12):1051-1057. doi: 10.1080/13543784.2019.1676725. Epub 2019 Nov 3. Expert Opin Investig Drugs. 2019. PMID: 31603362 Review.

2

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

Scott LJ. Scott LJ. CNS Drugs. 2020 Nov;34(11):1191-1200. doi: 10.1007/s40263-020-00771-z. Epub 2020 Oct 27. CNS Drugs. 2020. PMID: 33108633 Free PMC article. Review.

3

Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function.

Spampinato SF, Merlo S, Sano Y, Kanda T, Sortino MA. Spampinato SF, et al. Biochem Pharmacol. 2021 Apr;186:114465. doi: 10.1016/j.bcp.2021.114465. Epub 2021 Feb 10. Biochem Pharmacol. 2021. PMID: 33577891

4

Siponimod to treat secondary progressive multiple sclerosis.

Gajofatto A, Turatti M. Gajofatto A, et al. Drugs Today (Barc). 2020 Jan;56(1):37-46. doi: 10.1358/dot.2020.56.1.3091905. Drugs Today (Barc). 2020. PMID: 32055804 Review.

5

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.

Gajofatto A. Gajofatto A. Drug Des Devel Ther. 2017 Nov 2;11:3153-3157. doi: 10.2147/DDDT.S122249. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29138536 Free PMC article. Review.

6

Siponimod (Mayzent)--a new drug for multiple sclerosis.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 May 6;61(1571):70-72. Med Lett Drugs Ther. 2019. PMID: 31169805 No abstract available.

7

Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.

Colombo E, Bassani C, De Angelis A, Ruffini F, Ottoboni L, Comi G, Martino G, Farina C. Colombo E, et al. Front Immunol. 2020 Apr 8;11:635. doi: 10.3389/fimmu.2020.00635. eCollection 2020. Front Immunol. 2020. PMID: 32322257 Free PMC article.

8

Does Siponimod Exert Direct Effects in the Central Nervous System?

Kipp M. Kipp M. Cells. 2020 Jul 24;9(8):1771. doi: 10.3390/cells9081771. Cells. 2020. PMID: 32722245 Free PMC article. Review.

9

Siponimod for the treatment of secondary progressive multiple sclerosis.

Dumitrescu L, Constantinescu CS, Tanasescu R. Dumitrescu L, et al. Expert Opin Pharmacother. 2019 Feb;20(2):143-150. doi: 10.1080/14656566.2018.1551363. Epub 2018 Dec 5. Expert Opin Pharmacother. 2019. PMID: 30517042 Review.

10

Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.

Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R. Selkirk JV, et al. J Pharmacol Exp Ther. 2021 Dec;379(3):386-399. doi: 10.1124/jpet.121.000741. Epub 2021 Sep 17. J Pharmacol Exp Ther. 2021. PMID: 34535564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

186 results

Results by year